NRC Form 374A (7-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 22-16613-01

Docket or Reference number: 030-11330

Amendment No. 04

Samaritan Hospital
Department of Radiology
1515 Charles Avenue
St. Paul, MN 55104

In accordance with letter dated July 23, 1985, License Number 22-16613-01 is amended as follows:

Items 6., 7., 8., and 9. are amended to add:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
D. Iodine-125	D. Sealed sources (AECL Model Nos. C-234, C-235 or Amersham Corp. Model No. IMC.P2)	D. Two sources, No single source to exceed 300
E. Gadolinium-153	E. Sealed sources (Lunar Radiation Corp. GD Series)	E. Two sources, not to exceed 1.5 curies each

9. Authorized Use

D. One source to be used in a Lunar Radiation Corp. Model SP2 Forearm Scanner for bone densitometry. One source to be held in its shipping container incident to source exchange.

E. One source to be used in a Lunar Radiation Corp. Model DP3 Spine Scanner for bone densitometry. One source to be held in its shipping container incident to source exchange.

Conditions 12., 19. and 20. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Robert Schubert, M.D.	Groups I, II and III Gadolinium-153 and iodine-125 for bone imaging/densitometry
Stuart James Poljack, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Gadolinium-153 and iodine-125 for bone imaging/densitometry

8511190342 851001
REG3 LIC30
22-16613-01 PDR

1/1

COPY 2
ML20 CM 10/1/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 22-16613-01

Docket or Reference number: 030-11330

Amendment No. 04

James L. Purdie, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Gadlinium-153 and iodine-125 for bone imaging/densitometry
Quinton N. Anderson, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Gadolinium-153 and iodine-125 for bone imaging/densitometry
Joseph M. Melond, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dyfunction and thyroid carcinoma Gadolinium-153 and iodine-125 for bone minaging/densitometry

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated November 11, 1980 and July 25, 1985; letters dated May 26, 1981, November 18, 1983, May 2, 1984 and July 23, 1985; and ALARA Program dated November 7, 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

20. The Radiation Protection Officer for the activities authorized by this license is Quinten N. Anderaon, M.D.

Conditions 22. and 23. are added:

22. A. (1) Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
22-16613-01

Docket or Reference number
030-11330

Amendment No. 04

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within five (5) days of the test with the U. S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, describing the equipment involved, the test results, and the corrective action taken.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.

23. The licensee shall use the material listed in Subitems 6.D. and 6.E. in accordance with the device manufacturer's instruction manual. The exchange of sources in the Lunar Radiation Corp. Model DP3 Spine Scanner and SP2 Forearm Scanner shall be conducted by or under the supervision and in the physical presence of those individuals authorized to use gadolinium-153 and iodine-125 in Condition 12. of this license, who have completed the device manufacturer's training in source excahnge and have been designated by the radiation safety officer. The radiation safety officer shall maintain a record of each individual so designated.

For the U.S. Nuclear Regulatory Commission

OCT 1 1985

Date _____

Original Signed
By William J. Adam, Ph.D.
Materials Licensing Section, Region III

COPY